Answers are grounded in this paper and cite their sources.
Introduction and purpose. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, were introduced for glycaemic control and weight reduction, but a rapidly expanding body of evidence shows benefits that extend far beyond the scale. The purpose of this narrative review is to synthesise current evidence on the pleiotropic effects of GLP-1 RAs across cardiovascular, renal, hepatic, respiratory, neurological and addiction-related domains, and to examine the impact of these agents on body composition and the role of physical activity in preserving skeletal muscle. Description of the state of knowledge. Landmark randomised trials demonstrate reductions in major adverse cardiovascular events (SELECT, SUSTAIN-6, SOUL), slowed progression of chronic kidney disease (FLOW), resolution of metabolic dysfunction-associated steatohepatitis (ESSENCE) and marked improvement in obstructive sleep apnoea (SURMOUNT-OSA). These effects are only partly explained by weight loss and glucose lowering, implicating direct anti-inflammatory and tissue-protective mechanisms. A key limitation is that roughly one quarter of total weight lost is lean mass; evidence indicates that resistance and combined exercise can substantially attenuate this loss and preserve physical function. Summary. GLP-1 RAs have evolved into multi-organ cardiometabolic therapies. Combining pharmacotherapy with structured physical activity, particularly resistance training, appears essential to optimise the quality of weight loss and preserve muscle, linking pharmacology with exercise science.
No takes yet. Share an insight, caveat, or question.
Pieczara et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: